medigraphic.com

2002, Número 2

<< Anterior Siguiente >>

Enf Infec Microbiol 2002; 22 (2)


Actualidades en el tratamiento de infecciones por bacterias grampositivas

Hermida EEC, Suárez SS

Idioma: Español
Referencias bibliográficas: 31
Paginas: 62-68
Archivo PDF: 64.40 Kb.


RESUMEN

Los factores de riesgo para adquirir infecciones graves por cocos grampositivos son entre otros la edad, enfermedades subyacentes y el estado inmunológico. Las infecciones por S. aureus y S. pneumoniae han sufrido cambios epidemiológicos notables particularmente en el patrón de susceptibilidad lo que ha llevado a la presencia de infecciones bacterianas emergentes y reemergentes. En México por ejemplo, la etiología de las neumonías nosocomiales ha variado de bacterias gramnegativas a grampositivas. La creciente presencia resistencias en bacterias grampositivas ha llevado a elevar la morbi-mortalidad en infecciones causadas por estos microorganismos. Lo anterior ha llevado al desarrollo de nuevos antimicrobianos como las oxazolidinonas entre las que se encuentra el linezolid.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kirby WMM. Extraction of a highly potent penicillin inactivator from penicillin resistant Staphylococci. Science 1944;99:452-3.

  2. Barber M, Rozwadowska-Dowzenko M. Infection by penicillin-resistant Staphylococci. Lancet 1948;1:641-4.

  3. Jessen O, Rosendal K, Bulow V, Eriksen KR. Changing staphylococci and staphylococcal infections. A ten year study of bacterial and cases of bacteremia. N Engl J Med 1969;281: 627-35.

  4. Hand DI, Baker WA. Penicillin G of “rural” Staphylococcus aureus. J Fam Pract 1980;11:43-6

  5. Ross S, Rodriguez W, Controni G, Khan W. Staphylococcal susceptibility to penicillin G: The changing pattern among community isolates. JAMA 1974;229:1075-7.

  6. Adcock PM, Pastor P, Medley F, et al. Methicillin-resistant Sthapylococcus aureus in two child care centers. J Infect Dis 1998;280:1038-9.

  7. Ball P. Therapy for pneumococcal infection at the millennium: doubts and certainties. Am J Med 1999;107(Suppl 1A):77S-85S.

  8. Chen DK, McGeer A, De Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.

  9. Levin BR, Antia R, Berliner E, et al. Resistance to antimicrobial chemotherapy: a prescription for research and action. Am J Med Sci 1998;315:87-94.

  10. Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 1998;27:764-70.

  11. Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999;33:101-12.

  12. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: findings of the Alexander project 1992-1996. J Chemother 1999;11(Suppl 1):5-21.

  13. National Nosocomial Infections Surveillance (NNIS) System. Data summary from October 1986-April 1998. Atlanta: Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, 1998.

  14. Díaz-Ramos RD, Solórzano-Santos F, Padilla-Barrón G y cols. Infecciones nosocomiales. Experiencia en un hospital pediátrico de tercer nivel. Salud Pública Mex 1999;41(Suppl 1):S12-7.

  15. Tanaka M, Wada N, Kurosaka SM, Chiba M, Sato K, Hiramatsu K. In vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin. J Antimicrob Chemother 1998;42:552-3.

  16. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:813-5.

  17. Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Diagn Microbiol Infect Dis 1999;34:65-72.

  18. Saara Salmenlinna, Outi Lyytikäinen, Jaana Vuopio-Varkila. Community-Acquired Methicillin-Resistant Staphylococcus aureus, Finland Emerg Infect Dis 2002;8(6).

  19. Staphylococcus aureus Resistant to Vancomycin-United States, 2002. MMWR 2002;51(26):565-567.

  20. Brickner SJ. Oxazolidinone antibacterial agents. Curr Pharm Design 1996;2:175-194.

  21. Perry CM, Jarvis B, Linezolid. A review of the use in the management of serious gram positive infections. Drugs 2001;61:625-61.

  22. Zyvox (Linezolid) [package insert]. Kalamazoo Mich: Pharmacia & Upjohn; April 2000.

  23. Noskin GA, Siddiqul F, Stosor V, et al. In vitro activities of Linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059-2062.

  24. Duvall SE, Seas C, Bruss JB, et al. Comparison of Linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: results from a multinational phase III trial. In: Program and abstracts of the 9th International Congress of Infectious Diseases; April 10-13, 2000; Buenos Aires. Abstract 181.

  25. Cammerata SK, Bermudez M, Golin V, et al. Comparison of Linezolid versus ceftriaxone/cefpodoxime en the treatment of hospitalized community acquires pneumonia (abstract) 9th International Congress on Infectious Diseases; 200 Apr 10.13; Buenos Aires, 182.

  26. Cammarata SK, Hafkin B, Todd WM, et al. Efficacy of Linezolid in community-acquired S. pneumoniae pneumonia. Am J Respir Crit Care Med 1999;159(Suppl pt 2):A844.

  27. Lobeck F, Anderson DC, Bruss JB. Linezolid for the treatment of pneumonia in hospitalized children: an open-label. Single-arm, multicenter study (abstract) 9th International Congress on Infectious Diseases; 200 Apr 10.13; Buenos Aires, 117.

  28. Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia. Clin Infect Dis 2001;32:402-412.

  29. McNeil SA, Clark NM, Chandrasekar PH, et al. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with Linezolid after failure of therapy with Synercid (quinupristin/dalfopristin). Clin Infect Dis 2000;30: 403-404.

  30. Stevens LD, Herr D, Lampiris H , Hunt LJ, Batts HD, Hafkin B, and the Linezolid MRSA Study Group Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections. CID 2002;34:1481.

  31. Birmingham MC, Zimmer GS, Hafkin B, et al. Outcomes with Linezolid from an ongoing compassionate use trial of patients with significant, resistant, gram-positive infections. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 26-29, 1999; San Francisco. Abstract 1098.




2020     |     www.medigraphic.com